This project has provided research infrastructure support for the following clinical protocols: 03-AR-0298 A Pilot Study with the IL-1 Receptor Antagonist Anakinra or Kineret in Patients with Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) 05-AR-0014 Continuation of a Pilot Open-Label Study of IL 1 Trap in Adult Subjects with Autoinflammatory Disease: A Therapeutic Approach to Study Pathogenesis 03-AR-0173 Studies of the Natural History, Pathogenesis and Outcome of (NOMID / CAPS, DIRA, CRMO, Still's Disease, Behcet's Disease, and other Undifferentiated Autoinflammatory Diseases) 07-AR-0146 Analysis of Stored Identified Specimens from Patients Enrolled in Protocol Number 98-AR-0150 09-AR-0006 A Multi-Center, Open Label, 6-Month Treatment Study to Establish the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Canakinumab (anti-IL-1 Beta Antibody) in Patients with NOMID / CINCA Syndrome 11-AR-0241 A Pilot Study of Anakinra in Behcet's Disease (BD) 11-AR-0223 Studies on the Natural History and Pathogenesis of Spondyloarthritis 12-AR-8001 Compassionate Use Treatment Protocol 14V-MC-JAGA Treatment of Autoinflammatory Syndromes Expected to Benefit from JAK 1/2 Inhibition OFFICE OF THE CLINICAL DIRECTOR 91-AR-0196 Studies on the Natural History and Pathogenesis of Polymyositis, Dermatomyositis, and Related Diseases 94-AR-0066 Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE) 00-AR-0222 Studies of the Pathogenesis and Natural History of Arthritis and Related Conditions 01-AR-0227 Natural History of Rheumatic Disease in Minority Communities 02-AR-0156 A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab In Patients With Dermatomyositis and Polymyositis 02-AR-0131 Collection Of Blood Components Using Apheresis From Patients With Rheumatic Diseases And Healthy Volunteers 02-AR-0272 A Phase I, Open-Labeled, Dose-Ascending Clinical Trial of Immunotherapy of MRA, A Humanized Anti-IL 6 Receptor Monoclonal Antibody, In Patients with Systemic Lupus Erythematosus 08-D-N021 Role of the Antibody Against NR2 Glutamate Receptor in Cognitive Dysfunction in Patients with Systemic Lupus Erythematosis 08-AR-0008 Insulin Resistance and Atherosclerosis in a Sample of Women with Systemic Lupus Erythematosus 08-AR-0029 Phase Ib, MultiCenter Randomized, Double-Blind Placebo-Controlled, Dose Escalation Study w/Open-Label Extension to Evaluate Safety and Tolerability of Multiple IV Doses of MEDI-545;A Fully Human Anti-IFN-alpha Monoclonal Antibody in Patients w/SLE AUTOIMMUNITY BRANCH 99-AR-0004 Molecular Basis of Primary Immunodeficiencies CLINICAL TRIALS AND OUTCOMES BRANCH 03-AR-0130 Genetic Determinants of Ankylosing Spondylitis Severity - Cross Sectional Study 03-AR-0131 Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study 03-AR-0133 Clinically Important Changes in Rheumatoid Arthritis 04-AR-0205 Progression of Spinal Fusion in Ankylosing Spondylitis 11-AR-0156 Bisphosphanate Users Radiographic Characterisitics of the Hip (BURCH) NEW PROTOCOLS---IN PROCESS T-AR-0121 Safety and Tolerability of Omalizumab in Patients with Lupus T-AR-0141 A Pilot Open-Label Study of Rilonacept (Arcalyst) in the Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zip Code
Faridi, Mohd Hafeez; Khan, Samia Q; Zhao, Wenpu et al. (2017) CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus. J Clin Invest 127:1271-1283
Demirkaya, Erkan; Zhou, Qing; Smith, Carolyne K et al. (2017) Brief Report: Deficiency of Complement 1r Subcomponent in Early-Onset Systemic Lupus Erythematosus: The Role of Disease-Modifying Alleles in a Monogenic Disease. Arthritis Rheumatol 69:1832-1839
Lightfoot, Yaima L; Blanco, Luz P; Kaplan, Mariana J (2017) Metabolic abnormalities and oxidative stress in lupus. Curr Opin Rheumatol 29:442-449
Ward, Michael M; Guthrie, Lori C; Dasgupta, Abhijit (2017) Direct and Indirect Determinants of the Patient Global Assessment in Rheumatoid Arthritis: Differences by Level of Disease Activity. Arthritis Care Res (Hoboken) 69:323-329
Carmona-Rivera, Carmelo; Purmalek, Monica M; Moore, Erica et al. (2017) A role for muscarinic receptors in neutrophil extracellular trap formation and levamisole-induced autoimmunity. JCI Insight 2:e89780
Grayson, Peter C; Yazici, Yusuf; Merideth, Melissa et al. (2017) Treatment of mucocutaneous manifestations in Beh├žet's disease with anakinra: a pilot open-label study. Arthritis Res Ther 19:69
Furumoto, Yasuko; Smith, Carolyne K; Blanco, Luz et al. (2017) Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. Arthritis Rheumatol 69:148-160
Rhee, Rennie L; Grayson, Peter C; Merkel, Peter A et al. (2017) Response to eLetter: 'Infections in giant cell arteritis and therapeutic implications' by Moiseev et al. Ann Rheum Dis 76:e30
Aggarwal, Rohit; Rider, Lisa G; Ruperto, Nicolino et al. (2017) 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheu Ann Rheum Dis 76:792-801
Aggarwal, Rohit; Rider, Lisa G; Ruperto, Nicolino et al. (2017) 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheu Arthritis Rheumatol 69:898-910

Showing the most recent 10 out of 157 publications